vadimezan has been researched along with Cancer of Liver in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Jiang, Z; Liu, J; Liu, Z; Wang, H; Zhang, C; Zhang, J; Zhang, L | 1 |
| Chen, X; Du, L; Gu, Z; Hu, Q; Li, F; Li, J; Liu, P; Pu, J; Tang, Q; Wang, J; Wang, X; Xie, Y; Zhou, Y | 1 |
| Cathomas, R; Erdmann, A; Früh, M; Fustier, P; Krasniqi, F; Küttel, E; Mamot, C; Pless, M; Rauch, D; Siano, M; Simcock, M; Tscherry, G; Zippelius, A | 1 |
1 trial(s) available for vadimezan and Cancer of Liver
| Article | Year |
|---|---|
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Treatment Outcome; Xanthones | 2013 |
2 other study(ies) available for vadimezan and Cancer of Liver
| Article | Year |
|---|---|
Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
Topics: Antineoplastic Agents; Apoptosis; Hep G2 Cells; Humans; Liver Neoplasms; Nitrates; Nitric Oxide Donors; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Structure-Activity Relationship; Tumor Suppressor Protein p53; Xanthones | 2018 |
A DNA/DMXAA/Metal-Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity.
Topics: Animals; Carcinoma, Hepatocellular; DNA; Immunity, Innate; Liver Neoplasms; Membrane Proteins; Metal-Organic Frameworks; Mice; Tumor Microenvironment | 2023 |